Be a Smart Investor
Friday, November 25, 2016
Odd timing for J&J's proposed takeover of Actelion due to Trump: Pro
Alex Tarrant, assistant editor at Dealreporter Europe, weighs in on Johnson & Johnson's proposed acquisition of Swiss biotechnology company Actelion.
from Mergers and Acquisitions http://ift.tt/2fxJyGq
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment